Zeo ScientifiX update: Phase I Zofin trial complete, PPX revenue up $474K, partnerships expanded

Zeo ScientifiX, Inc.

Completed Phase I safety trials for flagship Zofin; plans to amend INDs for Phase II targeting Osteoarthrosis and COPD.
PPX autologous product revenue increased by approximately $474,000 in FY2024 compared to prior fiscal year.
Issued patents for amniotic fluid processing techniques and PPX blood-derived exosome pain treatment method in past year.
Strategic partnership with Physicians Group LLC, operating 75 clinics and 750 clinicians, for collaborative research and clinical trials.
Launched ZEO HAIR GROW topical product with Exotropin; aims at hair loss market affecting 35M men and 31M women in US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.